×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TOVX – theriva biologics, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TOVX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
04:05 pm
tovx
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
High
Report
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
3/23
08:00 am
tovx
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
High
Report
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
3/12
08:38 am
tovx
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results [Yahoo! Finance]
Low
Report
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results [Yahoo! Finance]
3/12
08:00 am
tovx
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
Low
Report
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
2/18
08:00 am
tovx
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
Medium
Report
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
2/3
08:00 am
tovx
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Medium
Report
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/20
05:24 pm
tovx
Form PRE 14A Theriva Biologics, Inc. For: Apr 20
High
Report
Form PRE 14A Theriva Biologics, Inc. For: Apr 20
4/17
04:15 pm
tovx
Form 8-K Theriva Biologics, Inc. For: Apr 17
High
Report
Form 8-K Theriva Biologics, Inc. For: Apr 17
4/9
04:15 pm
tovx
Form 8-K Theriva Biologics, Inc. For: Apr 09
High
Report
Form 8-K Theriva Biologics, Inc. For: Apr 09
3/23
08:10 am
tovx
Form 8-K Theriva Biologics, Inc. For: Mar 23
Low
Report
Form 8-K Theriva Biologics, Inc. For: Mar 23
3/16
05:32 pm
tovx
Form DEF 14A Theriva Biologics, Inc. For: Apr 09
Low
Report
Form DEF 14A Theriva Biologics, Inc. For: Apr 09
3/12
08:16 am
tovx
Form 10-K Theriva Biologics, Inc. For: Dec 31
Low
Report
Form 10-K Theriva Biologics, Inc. For: Dec 31
3/12
08:11 am
tovx
Form 8-K Theriva Biologics, Inc. For: Mar 12
Low
Report
Form 8-K Theriva Biologics, Inc. For: Mar 12
3/4
04:35 pm
tovx
Form PRE 14A Theriva Biologics, Inc. For: Mar 04
Low
Report
Form PRE 14A Theriva Biologics, Inc. For: Mar 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: